UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                  ------------

                                    FORM 6-K

                                  ------------

                            REPORT OF FOREIGN ISSUER

                       Pursuant to Rule 13a-16 or 15d-16
                     of the Securities Exchange Act of 1934


                                February 16, 2010


                                  ------------

                                NOVO NORDISK A/S
             (Exact name of Registrant as specified in its charter)


                                    NOVO ALLE
                               DK-2880, BAGSVAERD
                                     DENMARK
                    (Address of principal executive offices)

                                  ------------

Indicate by check mark whether the registrant files or will file annual reports
under cover of Form 20-F or Form 40-F

                       Form 20-F [X]     Form 40-F [ ]


Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

                             Yes [ ]     No [X]


If "Yes" is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g-32(b):82-_____________________





TRANSACTION IN OWN SHARES

NOVO NORDISK A/S - SHARE REPURCHASE PROGRAMME

On 2 February 2010 Novo Nordisk initiated its share repurchase programme in
accordance with the provisions of the European Commission's regulation no
2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Under the programme Novo Nordisk will repurchase B shares for an amount up to
DKK 2.0 billion in the period from 2 February 2010 to 26 April 2010.

Since the announcement as of 8 February 2010, the following transactions have
been made under the programme:

                                NUMBER OF             AVERAGE        TRANSACTION
                                   SHARES      PURCHASE PRICE        VALUE,  DKK
ACCUMULATED, LAST
ANNOUNCEMENT                      435,000                            162,272,753
08 February 2010                   90,000            373.8999         33,650,991
09 February 2010                   90,000            374.0000         33,660,000
10 February 2010                   90,000            374.0290         33,662,610
11 February 2010                   90,000            378.7490         34,087,410
12 February 2010                   90,000            385.0110         34,650,990
ACCUMULATED UNDER THE
PROGRAMME                         885,000                            331,984,754

Transactions related to Novo Nordisk's incentive programmes have resulted in a
net sale by Novo Nordisk of 359,222 B shares in the period from 8 February 2010
to 12 February 2010. The shares in these transactions were not part of the Safe
Harbour repurchase programme.

With the transactions stated above, Novo Nordisk owns a total of 31,281,948
treasury shares, corresponding to 5.0% of the share capital. The total amount of
shares in the company is 620,000,000 including treasury shares.

Novo Nordisk is a healthcare company and a world leader in diabetes care. In
addition, Novo Nordisk has a leading position within areas such as haemostasis
management, growth hormone therapy and hormone replacement therapy. Novo Nordisk
manufactures and markets pharmaceutical products and services that make a
significant difference to patients, the medical profession and society. With
headquarters in Denmark, Novo Nordisk employs more than 29,300 employees in 76
countries, and markets its products in 179 countries. Novo Nordisk's B shares
are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed
on the New York Stock Exchange under the symbol 'NVO'. For more information,
visit novonordisk.com.


Further information:

Media:                          Investors:

Elin K Hansen                   Klaus Bulow Davidsen
Tel: (+45) 4442 3450            Tel: (+45) 4442 3176
ekh@novonordisk.com             klda@novonordisk.com

                                Kasper Roseeuw Poulsen
                                Tel: (+45) 4442 4471
                                krop@novonordisk.com

In North America:               In North America:
Sean Clements                   Hans Rommer
Tel: (+1) 609 514 8316          Tel: (+1) 609 919 7937
secl@novonordisk.com            hrmm@novonordisk.com


Company Announcement no 9 / 2010



                                   SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf of the
undersigned, thereunto duly authorized.

Date: February 16, 2010                        NOVO NORDISK A/S
                             ---------------------------------------------------
                                            Lars Rebien Sorensen,
                                     President and Chief Executive Officer